- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00059826
Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer
A Phase II Study of Interferon-Based Adjuvant Chemoradiation in Patients With Resected Pancreatic Adenocarcinoma
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of tumor cells. Radiation therapy uses high-energy radiation from x-rays and other sources to kill tumor cells. Combining chemotherapy with interferon alfa and giving them with radiation therapy after surgery may kill any remaining tumor cells.
PURPOSE: Phase II trial to study the effectiveness of adjuvant chemoradiotherapy and interferon alfa in treating patients who have resected stage I, stage II, or stage III pancreatic cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
- Determine the disease-free and overall survival of patients with resected pancreatic adenocarcinoma treated with adjuvant chemoradiotherapy comprising fluorouracil, cisplatin, and interferon alfa.
- Determine the rate and severity of acute and late toxic effects in patients treated with this regimen.
- Determine the local-regional disease control and distant disease control in patients treated with this regimen.
OUTLINE: This is a multicenter study.
- Chemoradiotherapy (CRT): Patients receive fluorouracil IV continuously on days 1-38; cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36; and interferon alfa subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, and 38. Patients also undergo radiotherapy on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38.
- Post-CRT chemotherapy: Beginning 4-6 weeks after the completion of CRT, patients receive fluorouracil IV continuously on days 1-42. Treatment repeats every 56 days for a total of two courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 2 months for 2 years, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Gainesville, Florida, Forente stater, 32610-0232
- University of Florida Shands Cancer Center
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60612
- Rush University Medical Center
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- James Graham Brown Cancer Center at University of Louisville
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Forente stater, 02115
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
-
Boston, Massachusetts, Forente stater, 02114
- Massachusetts General Hospital Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455
- Fairview University Medical Center - University Campus
-
-
New York
-
Buffalo, New York, Forente stater, 14263-0001
- Roswell Park Cancer Institute
-
New York, New York, Forente stater, 10021
- Memorial Sloan-Kettering Cancer Center
-
Rochester, New York, Forente stater, 14642
- James P. Wilmot Cancer Center at University of Rochester Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt-Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, Forente stater, 75231
- Presbyterian Hospital of Dallas
-
Houston, Texas, Forente stater, 77030
- Baylor University Medical Center - Houston
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Medical College of Wisconsin Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patient must be > 18 years of age.
- Patient must have a documented ECOG/Zubrod performance status of 0 or 1, within 7 days prior to registration.
Patient must have pathological stage T1-3, N0-1, M0 adenocarcinoma of the head of the pancreas according to the American Joint Committee on Cancer (AJCC) staging system.
- NOTE: The pathology report must be submitted to ACOSOG on the Pathology Report Shuttle CRF.
- Patient must have undergone a potentially curative gross total resection by pancreaticoduodenectomy (includes R0 [no residual tumor] or R1 [microscopic residual tumor]) within 56 days prior to beginning treatment. NOTE: The operative report must be submitted to ACOSOG on the Operative Report Shuttle CRF.
Patient must have stable or increasing weight in the 14 days prior to the start of treatment, otherwise supplemental nutrition (e.g. feeding jejunostomy, PEG, TPN) must be initiated prior to the start of treatment.6. Patient must have adequate bone marrow, hepatic and renal function, within 7 days prior to registration:
- WBC > 3,000 mm^3
- ANC > 1,500 mm^3
- hemoglobin > 9.5 mg/dl
- platelet count > 100,000 mm^3
- total bilirubin < 3 mg/dl
- AST (SGOT) < 2.0 times institutional upper limit of normal (ULN)
- ALT (SGPT) < 2.0 times institutional ULN
- alkaline phosphatase < 2.0 times institutional ULN
- serum creatinine < 1.5 times institutional ULN
7. Patient must have a baseline diagnostic CT scan of the chest and CT scan with IV contrast (or MRI) of abdomen/pelvis, within 30 days prior to registration, to exclude metastatic disease.
8. If female of childbearing potential, patient must have a negative urine or serum pregnancy test, within 7 days prior to registration. NOTE: Postmenopausal women must have been amenorrheic for at least 12 consecutive months to be considered not of childbearing potential.
9. Patient (male or female) of reproductive potential must agree to use medically acceptable contraception during the study. NOTE: Medically acceptable contraceptives include: (1) surgical sterilization, (2) approved hormonal contraceptives (such as birth control pills, Depo-Provera, or Lupron Depot), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD).
10. Patient, or the patient's legally acceptable representative, must sign and date an informed consent PRIOR to registration and the performance of any study related procedures.
11. Patient, or the patient's legally acceptable representative, must provide written authorization to allow the use and disclosure of their protected health information.
- NOTE: This may be obtained in either the study-specific informed consent or in a separate authorization form and must be obtained from the patient prior to study registration.
12. If patient is a cancer survivor, all of the following criteria must be met and documented in the patient's medical record:
- Patient has undergone potentially curative therapy for all prior malignancies.
- No evidence of prior malignancies for at least 5 years (except for successfully treated cervical carcinoma in situ, lobular carcinoma in situ of the breast, or nonmelanoma skin cancer).
- No evidence of recurrence of any prior malignancy.
Exclusion Criteria:
- Patient has pancreaticoduodenectomy histopathology of adenosquamous carcinoma, ampullary carcinoma, carcinoid tumor, cystadenocarcinoma, cystadenoma, distal common bile duct carcinoma, duodenal carcinoma, or islet cell carcinoma.
- Patient is pregnant or lactating.
- Patient has recurrent pancreatic cancer.
- Patient has received prior systemic chemotherapy or radiotherapy for pancreatic cancer.
- Patient has received external beam photon (x-ray) therapy to the chest, abdomen or pelvis.
- Patient has received any biologic/ immunologic therapies.
- Patient has received chronic immunotherapy (e.g. prednisone or methotrexate) for collagen vascular disease or other chronic immunologic abnormality.
- Patient has a preexisting psychiatric condition, especially depression, or a history of severe psychiatric disorders.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Interferon-based chemoradiation therapy
Cycle 1: Chemoradiotherapy (CRT)
Cycles 2 and 3: Post-CRT Chemotherapy Post-CRT chemotherapy starts 4 - 6 weeks after completion of Cycle 1, unless the study physician deems further delay is necessary. Patients will be given 2 cycles of chemotherapy (cycles 2 and 3). -- 5-fluorouracil continuous infusion via an ambulatory infusion pump into a central venous catheter at 200 mg/m2/day for 6 weeks followed by 2 weeks of rest |
Andre navn:
IV
IV
Andre navn:
IV
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Overall survival at 18 months
Tidsramme: at 18 months
|
at 18 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Toxicity
Tidsramme: at 18 months
|
at 18 months
|
Sykdomsfri overlevelse
Tidsramme: ved 18 måneder
|
ved 18 måneder
|
Local-regional disease control
Tidsramme: at 18 months
|
at 18 months
|
Distant disease control
Tidsramme: at 18 months
|
at 18 months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: Vincent J. Picozzi, MD, Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Picozzi VJ, Abrams RA, Decker PA, Traverso W, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Rothenberg ML, Posner MC, Pisters PW; American College of Surgeons Oncology Group. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011 Feb;22(2):348-54. doi: 10.1093/annonc/mdq384. Epub 2010 Jul 29.
- Picozzi VJ, Abrams RA, Traverso LW, et al.: ACOSOG Z05031: initial report of a multicenter, phase II trial of a novel chemoradiation protocol using cisplatin, 5-FU, and alpha- interferon as adjuvant therapy for resected pancreas cancer. [Abstract] American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, 25-27 January 2008, Orlando, FL. A-125, 2008.
- Picozzi VJ, Abrams RA, Traverso LW, et al.: ACOSOG Z05031: report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5- FU, and alpha-interferon. [Abstract] J Clin Oncol 26 (Suppl 15): A-4505, 2008.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer
- Neoplasmer etter nettsted
- Sykdommer i det endokrine systemet
- Neoplasmer i fordøyelsessystemet
- Neoplasmer i endokrine kjertel
- Pankreassykdommer
- Neoplasmer i bukspyttkjertelen
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Interferoner
- Interferon-alfa
- Fluorouracil
- Interferon alfa-2
Andre studie-ID-numre
- ACOSOG-Z05031
- CDR0000298776 (Registeridentifikator: NCI Physician Data Query)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Bukspyttkjertelkreft
-
Tianjin Medical University Cancer Institute and...Har ikke rekruttert ennåPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaKina
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalia
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalia
-
Cedars-Sinai Medical CenterRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaForente stater
-
Radboud University Medical CenterDutch Cancer SocietyRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaNederland
-
Thomas Jefferson UniversityUkjentBukspyttkjertelfistel | Distal pankreatektomikomplikasjoner | Falciform Patch Pancreatic Closure | Fibrinlim bukspyttkjertellukkingForente stater
-
Imperial College LondonThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS... og andre samarbeidspartnereRekrutteringBukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaStorbritannia
-
Chinese PLA General HospitalRekrutteringNeoplasmer i bukspyttkjertelen | Bukspyttkjertelkreft | Bukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaKina
-
Andrei IagaruIkke lenger tilgjengeligKarsinoide svulster | Islet Cell (Pancreatic NET) | Andre nevroendokrine svulsterForente stater
Kliniske studier på strålebehandling
-
Alpha Tau Medical LTD.RekrutteringLungekreft | Tilbakevendende lungekreftIsrael
-
Alpha Tau Medical LTD.RekrutteringHudkreft | Slimhinneneoplasma i munnhulen | MykvevsneoplasmaIsrael
-
Alpha Tau Medical LTD.RekrutteringProstata adenokarsinomIsrael
-
Alpha Tau Medical LTD.European Organisation for Research and Treatment of Cancer - EORTCHar ikke rekruttert ennåPlateepitelkarsinom i hode og nakke | PlateepitelkarsinomIsrael
-
Alpha Tau Medical LTD.RekrutteringHudkreft | Slimhinneneoplasma i munnhulen | MykvevsneoplasmaIsrael
-
Alpha Tau Medical LTD.AvsluttetMetastatisk brystkreft | Brystkarsinom | Invasiv brystkreft | Fjernmetastaser. PatologiDen russiske føderasjonen
-
Alpha Tau Medical LTD.FullførtPlateepitelkarsinom i hudenItalia
-
Alpha Tau Medical LTD.RekrutteringHudkreft | Slimhinneneoplasma i munnhulen | MykvevsneoplasmaItalia
-
Alpha Tau Medical LTD.Aktiv, ikke rekrutterendeHudkreft | Slimhinneneoplasma i munnhulen | MykvevsneoplasmaIsrael
-
Alpha Tau Medical LTD.RekrutteringHudkreft | Slimhinneneoplasma i munnhulen | MykvevsneoplasmaIsrael